Lipocine Inc. (LPCN) is a publicly traded Healthcare sector company. As of May 21, 2026, LPCN trades at $2.24 with a market cap of $18.22M and a P/E ratio of 0.00. LPCN moved +2.27% today. Year to date, LPCN is -69.32%; over the trailing twelve months it is -38.46%. Its 52-week range spans $1.81 to $12.37. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces LPCN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Lipocine Phase 3 PPD Trial Fails; Q1 Net Loss of $0.52/Share: Lipocine’s Phase 3 trial of LPCN 1154 for postpartum depression missed its primary endpoint at hour 60 but showed no serious adverse events or excessive sedation. In Q1, cash was $24.7 million, net loss widened to $3.7 million ($0.52/share), R&D costs rose to $2.8 million and TLANDO royalties reached $119,000.
| Metric | Value |
|---|---|
| Price | $2.24 |
| Market Cap | $18.22M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.37 |
| 52-Week Low | $1.81 |
| Volume | 35 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.00M |
| Net Income | $-11.43M |
| Gross Margin | 0.00% |
2 analysts cover LPCN: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.